SciVision Biotech: 2025 net profit fell to NT$162,338,000 from NT$242,254,000

what happened

According to Dow Jones Newswires, citing the Taiwan Stock Exchange, SciVision Biotech Inc. has published its financial figures. For the 12 months ended December 31, 2025, revenue came in at NT$886,622,000 against NT$883,310,000 a year earlier, pretax profit fell to NT$185,040,000 from NT$291,598,000, and net profit dropped to NT$162,338,000 from NT$242,254,000. Basic earnings per share were 2.24, compared with 3.51.

In the second quarter of 2026, ended June 30, revenue rose to NT$211,026,000 from NT$209,487,000, and the company posted net profit of NT$34,644,000 compared with a loss of NT$16,030,000 a year earlier. Basic earnings per share were 0.47, against a loss of 0.22. For the first quarter of 2026, revenue, pretax profit and net profit of NT$21,956,000 matched the same period of 2025, as did earnings per share of 0.29.

why it matters

For markets this is a report from a small Taiwanese company with limited reach beyond its own shareholders. The swing back to profit in the second quarter after a loss a year earlier is noticeable, but one quarter does not establish a lasting trend, while the annual decline in profit is substantial.

tags

instruments